Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Candidemia Epidemiology Forecast

DelveInsight’s ‘Candidemia – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Candidemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017–2030


Candidemia Disease Understanding

Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on the skin without causing any problems. However, in certain patients who are at risk, Candida can enter the bloodstream or internal organs and cause an infection. A Candida bloodstream infection, also called candidemia, is the most common form of invasive candidiasis. 


Several studies were used to evaluate the hospitalization rate and ICU inpatients. For the US, Healthcare Cost and Utilization Project database was used to project hospital admissions and ICU patients. Regional literature publications were referred for admissions data across EU5 and Japan. It was noted that hospitalization rates were higher in Germany and the United Kingdom, this was also expected as both countries have almost complete health insurance coverage of their populations. National burden studies were referred to get estimates of reported candidemia incidence, most of these studies do not include prophylaxis, pre-emptive, and empirical treatment. The numbers were found to be underestimating the true magnitude of the infections.


Across 7MM it was noticed that men are more likely to get infected as compared to women, representing 55%-77% of the total cases. An increased risk was seen in the neonatal population, past 1 year of age risk of infection increased with age, forty-two percent of cases occurred in patients aged ≥ 65 years.


Candidemia is defined as the presence of Candida species in the blood. It is the most common fungal bloodstream infection in hospitalized patients. Mortality is very high. It reaches almost 50% in some studies. Although Candida albicans are still the most common Candida species causing candidemia, in recent years there has been an increase in non-albicans Candida species. The most common risk factors include critical illness and prolonged intensive care unit stay. The presence of a central venous catheter, antibiotic exposure, abdominal surgery (especially if repeated laparotomies or anastomotic leakage is present), malignancy (solid organ and hematologic), acute necrotizing pancreatitis, organ transplant recipients, and total parenteral nutrition are other major risk factors.


Many unmet needs are associated with this disorder; the lack of effectiveness of currently available therapeutics. A progressive shift from C. albicans to non-albicans Candida spp. is also observed in most parts of the world, probably related to the increased exposure to azoles. Therefore new therapies are needed to counter this. Timely diagnosis is one of the most important unmet needs. Therefore, it becomes imperative that such needs are fulfilled to have an efficient and reliable method to treat this disease.


Candidemia Epidemiology

The Candidemia epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of our report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

  • The total incident cases of Candidemia patients are increasing by 7MM during the study period, i.e. 2017–2030.
  • The disease epidemiology covered in the report provides historical as well as forecasted Candidemia symptoms epidemiology segmented as the Total incident cases of Candidemia, Gender-specific cases of Candidemia, Age-specific cases of Candidemia, Total patients receiving antifungal treatment targeting Candida. The report includes the incident scenario of Candidemia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.


Country-wise - Candidemia Epidemiology

The epidemiology segment also provides the Candidemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total incident cases of Candidemia associated in 7MM countries were 40,655 in 2017.

  • As per the estimates, the United States has the largest incident population of Candidemia.
  • Among the EU5 countries, Spain had the highest incident cases of Candidemia, followed by Germany. On the other hand, the UK had the lowest incident cases with 2,332 cases in 2017 in EU5.


Scope of the Report

  • The Candidemia report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The Candidemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Candidemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Candidemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Candidemia.
  • The report provides the segmentation of the Candidemia epidemiology by Incident Cases of Candidemia in 7MM.
  • The report provides the segmentation of the Candidemia epidemiology by Gender-specific Incident Cases of Candidemia in 7MM.
  • The report provides the segmentation of the Candidemia epidemiology by Age-specific Incident Cases of Candidemia in 7MM.
  • The report provides the segmentation of the Candidemia epidemiology by Total patients receiving antifungal treatment targeting Candida in 7MM.


Report Highlights

  • 11-year Forecast of Candidemia epidemiology
  • 7MM Coverage
  • Total Incident Cases of Candidemia
  • Incident Cases according to segmentation: Gender-specific cases of Candidemia
  • Incident Cases according to segmentation: Age-specific cases of Candidemia
  • Incident Cases according to segmentation: Total patients receiving antifungal treatment targeting Candida   


KOL- Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Candidemia?
  • What are the key findings of the Candidemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
  • What would be the total number of patients of Candidemia across the 7MM during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2017–2030)?
  • What are the disease risk, burdens, and unmet needs of the Candidemia?
  • What are the currently available treatments for Candidemia?


Reasons to buy

The Candidemia epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Candidemia market
  • Quantify patient populations in the global Candidemia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Candidemia therapeutics in each of the markets covered
  • Understand the magnitude of Candidemia population by its Incidence cases
  • Understand the magnitude of Candidemia population by its Gender-specific cases
  • Understand the magnitude of Candidemia population by its Age-specific cases
  • Understand the magnitude of Candidemia population by its total patients receiving antifungal treatment targeting Candida
  • The Candidemia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Candidemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Candidemia: Market Overview at a Glance

5.1 Total Market Share (%) Distribution of Candidemia in 2017

5.2 Total Market Share (%) Distribution of Candidemia in 2030

6 Candidemia: Market Overview at a Glance

6.1 Introduction

6.2 Pathophysiology

6.3 Differential Diagnosis

6.4 Disorder Subdivision

6.5 Sign and symptoms

6.6 Risk Factors

6.7 Diagnosis

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Assumptions and Rationale

7.3 Total cases of Candidemia in 7MM

7.4 United States

7.4.1 Total Incident cases of Candidemia in the United States

7.4.2 Gender-Specific cases of Candidemia in the United States

7.4.3 Age-specific cases of Candidemia in the United States

7.4.4 Total patients receiving antifungal treatment targeting Candida in the United States

7.5 EU5 Countries

7.6 Germany

7.6.1 Total Incident cases of Candidemia in Germany

7.6.2 Gender-Specific cases of Candidemia in Germany

7.6.3 Age-specific cases of Candidemia in Germany

7.6.4 Total patients receiving antifungal treatment targeting Candida in Germany

7.7 France

7.7.1 Total Incident cases of Candidemia in France

7.7.2 Gender-Specific cases of Candidemia in France

7.7.3 Age-specific cases of Candidemia in France

7.7.4 Total patients receiving antifungal treatment targeting Candida in France

7.8 Italy

7.8.1 Total Incident cases of Candidemia in Italy

7.8.2 Gender-Specific cases of Candidemia in Italy

7.8.3 Age-specific cases of Candidemia in Italy

7.8.4 Total patients receiving antifungal treatment targeting Candida in Italy

7.9 Spain

7.9.1 Total Incident cases of Candidemia in Spain

7.9.2 Gender-Specific cases of Candidemia in Spain

7.9.3 Age-specific cases of Candidemia in Spain

7.9.4 Total patients receiving antifungal treatment targeting Candida in Spain

7.1 UK

7.10.1 Total Incident cases of Candidemia in the United Kingdom

7.10.2 Gender-Specific cases of Candidemia in the United Kingdom

7.10.3 Age-specific cases of Candidemia in the United Kingdom

7.10.4 Total patients receiving antifungal treatment targeting Candida in the United Kingdom

7.11 Japan

7.11.1 Total Incident cases of Candidemia in Japan

7.11.2 Gender-Specific cases of Candidemia in Japan

7.11.3 Age-specific cases of Candidemia in Japan

7.11.4 Total patients receiving antifungal treatment targeting Candida in Japan

8 KOL Views

9 Bibliography

10 Appendix

10.1 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables

Table 1: Clinical condition or risk factor associated with different Candida species

Table 2: Total cases of Candidemia in 7MM (2017–2030)

Table 3: Total Incident cases of Candidemia in the United States (2017–2030)

Table 4: Gender-specific cases of Candidemia in the US (2017–2030)

Table 5: Age-specific cases of Candidemia in the US (2017–2030)

Table 6: Total patients receiving antifungal treatment targeting Candida in the US (2017–2030)

Table 7: Total Incident cases of Candidemia in Germany (2017–2030)

Table 8: Gender-specific cases of Candidemia in Germany (2017–2030)

Table 9: Age-specific cases of Candidemia in Germany (2017–2030)

Table 10: Total patients receiving antifungal treatment targeting Candida in Germany (2017–2030)

Table 11: Total Incident cases of Candidemia in France (2017–2030)

Table 12: Gender-specific cases of Candidemia in France (2017–2030)

Table 13: Age-specific cases of Candidemia in France (2017–2030)

Table 14: Total patients receiving antifungal treatment targeting Candida in France (2017–2030)

Table 15: Total Incident cases of Candidemia in Italy (2017–2030)

Table 16: Gender-specific cases of Candidemia in Italy (2017–2030)

Table 17: Age-specific cases of Candidemia in Italy (2017–2030)

Table 18: Total patients receiving antifungal treatment targeting Candida in Italy (2017–2030)

Table 19: Total Incident cases of Candidemia in Spain (2017–2030)

Table 20: Gender-specific cases of Candidemia in Spain (2017–2030)

Table 21: Age-specific cases of Candidemia in Spain (2017–2030)

Table 22: Total patients receiving antifungal treatment targeting Candida in Spain (2017–2030)

Table 23: Total Incident cases of Candidemia in the United Kingdom (2017–2030)

Table 24: Gender-specific cases of Candidemia in the UK (2017–2030)

Table 25: Age-specific cases of Candidemia in the UK (2017–2030)

Table 26: Total patients receiving antifungal treatment targeting Candida in the UK (2017–2030)

Table 27: Total Incident cases of Candidemia in Japan (2017–2030)

Table 28: Gender-specific cases of Candidemia in Japan (2017–2030)

Table 29: Age-specific cases of Candidemia in Japan (2017–2030)

Table 30: Total patients receiving antifungal treatment targeting Candida in Japan (2017–2030)

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Total cases of Candidemia in 7MM (2017–2030)

Figure 3: Total Incident cases of Candidemia in the United States (2017–2030)

Figure 4: Gender-Specific cases of Candidemia in the US (2017–2030)

Figure 5: Age-specific cases of Candidemia in the US (2017–2030)

Figure 6: Total patients receiving antifungal treatment targeting Candida in the US (2017–2030)

Figure 7: Total Incident cases of Candidemia in Germany (2017–2030)

Figure 8: Gender-Specific cases of Candidemia in Germany (2017–2030)

Figure 9: Age-specific cases of Candidemia in Germany (2017–2030)

Figure 10: Total patients receiving antifungal treatment targeting Candida in Germany (2017–2030)

Figure 11: Total Incident cases of Candidemia in France (2017–2030)

Figure 12: Gender-Specific cases of Candidemia in France (2017–2030)

Figure 13: Age-specific cases of Candidemia in France (2017–2030)

Figure 14: Total patients receiving antifungal treatment targeting Candida in France (2017–2030)

Figure 15: Total Incident cases of Candidemia in Italy (2017–2030)

Figure 16: Gender-Specific cases of Candidemia in Italy (2017–2030)

Figure 17: Age-specific cases of Candidemia in Italy (2017–2030)

Figure 18: Total patients receiving antifungal treatment targeting Candida in Italy (2017–2030)

Figure 19: Total Incident cases of Candidemia in Spain (2017–2030)

Figure 20: Gender-Specific cases of Candidemia in Spain (2017–2030)

Figure 21: Age-specific cases of Candidemia in Spain (2017–2030)

Figure 22: Total patients receiving antifungal treatment targeting Candida in Spain (2017–2030)

Figure 23: Total Incident cases of Candidemia in the United Kingdom (2017–2030)

Figure 24: Gender-Specific cases of Candidemia in the UK (2017–2030)

Figure 25: Age-specific cases of Candidemia in the UK (2017–2030)

Figure 26: Total patients receiving antifungal treatment targeting Candida in the UK (2017–2030)

Figure 27: Total Incident cases of Candidemia in Japan (2017–2030)

Figure 28: Gender-Specific cases of Candidemia in Japan (2017–2030)

Figure 29: Age-specific cases of Candidemia in Japan (2017–2030)

Figure 30: Total patients receiving antifungal treatment targeting Candida in Japan (2017–2030)

Forward to Friend

Need A Quote